Cargando…

Global Cancer Drug Development—A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting

Rapidly expanding systemic treatment options, combined with improved screening, diagnostic, surgical, and radiotherapy techniques, have led to improved survival outcomes for many cancers over time. However, these overall survival gains have disproportionately benefited patients in high-income countr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Brooke E., Sullivan, Richard, Peto, Richard, Abubakar, Bello, Booth, Christopher, Werutsky, Gustavo, Adams, Cary, Saint-Raymond, Agnes, Fleming, Thomas R., Lyerly, Kim, Gralow, Julie R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645408/
https://www.ncbi.nlm.nih.gov/pubmed/37944089
http://dx.doi.org/10.1200/GO.23.00294
_version_ 1785134746867597312
author Wilson, Brooke E.
Sullivan, Richard
Peto, Richard
Abubakar, Bello
Booth, Christopher
Werutsky, Gustavo
Adams, Cary
Saint-Raymond, Agnes
Fleming, Thomas R.
Lyerly, Kim
Gralow, Julie R.
author_facet Wilson, Brooke E.
Sullivan, Richard
Peto, Richard
Abubakar, Bello
Booth, Christopher
Werutsky, Gustavo
Adams, Cary
Saint-Raymond, Agnes
Fleming, Thomas R.
Lyerly, Kim
Gralow, Julie R.
author_sort Wilson, Brooke E.
collection PubMed
description Rapidly expanding systemic treatment options, combined with improved screening, diagnostic, surgical, and radiotherapy techniques, have led to improved survival outcomes for many cancers over time. However, these overall survival gains have disproportionately benefited patients in high-income countries, whereas patients in low- and middle-income countries (LMICs) continue to experience challenges in accessing timely and guideline concordant care. In September 2022, the Accelerating Anticancer Agent Development and Validation workshop was held, focusing on global cancer drug development. Panelists discussed key barriers such as the lack of diagnostic services and human resources, drug accessibility and affordability, lack of research infrastructure, and regulatory and authorization challenges, with a particular focus on Africa and Latin America. Potential opportunities to improve access and affordability were reviewed, such as the importance of prioritizing investments in diagnostics, investing health infrastructure and work force planning, coordinated drug procurement efforts and streamlined regulatory processing, incentivized pricing through regulatory change, and the importance of developing and promoting clinical trials that can answer relevant clinical questions for patients in LMICs. As a cancer community, we must continue to advocate for and work toward equitable access to high-quality interventions for patients, regardless of their geographical location.
format Online
Article
Text
id pubmed-10645408
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-106454082023-11-09 Global Cancer Drug Development—A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting Wilson, Brooke E. Sullivan, Richard Peto, Richard Abubakar, Bello Booth, Christopher Werutsky, Gustavo Adams, Cary Saint-Raymond, Agnes Fleming, Thomas R. Lyerly, Kim Gralow, Julie R. JCO Glob Oncol SPECIAL ARTICLES Rapidly expanding systemic treatment options, combined with improved screening, diagnostic, surgical, and radiotherapy techniques, have led to improved survival outcomes for many cancers over time. However, these overall survival gains have disproportionately benefited patients in high-income countries, whereas patients in low- and middle-income countries (LMICs) continue to experience challenges in accessing timely and guideline concordant care. In September 2022, the Accelerating Anticancer Agent Development and Validation workshop was held, focusing on global cancer drug development. Panelists discussed key barriers such as the lack of diagnostic services and human resources, drug accessibility and affordability, lack of research infrastructure, and regulatory and authorization challenges, with a particular focus on Africa and Latin America. Potential opportunities to improve access and affordability were reviewed, such as the importance of prioritizing investments in diagnostics, investing health infrastructure and work force planning, coordinated drug procurement efforts and streamlined regulatory processing, incentivized pricing through regulatory change, and the importance of developing and promoting clinical trials that can answer relevant clinical questions for patients in LMICs. As a cancer community, we must continue to advocate for and work toward equitable access to high-quality interventions for patients, regardless of their geographical location. Wolters Kluwer Health 2023-11-09 /pmc/articles/PMC10645408/ /pubmed/37944089 http://dx.doi.org/10.1200/GO.23.00294 Text en © 2023 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle SPECIAL ARTICLES
Wilson, Brooke E.
Sullivan, Richard
Peto, Richard
Abubakar, Bello
Booth, Christopher
Werutsky, Gustavo
Adams, Cary
Saint-Raymond, Agnes
Fleming, Thomas R.
Lyerly, Kim
Gralow, Julie R.
Global Cancer Drug Development—A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting
title Global Cancer Drug Development—A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting
title_full Global Cancer Drug Development—A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting
title_fullStr Global Cancer Drug Development—A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting
title_full_unstemmed Global Cancer Drug Development—A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting
title_short Global Cancer Drug Development—A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting
title_sort global cancer drug development—a report from the 2022 accelerating anticancer agent development and validation meeting
topic SPECIAL ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645408/
https://www.ncbi.nlm.nih.gov/pubmed/37944089
http://dx.doi.org/10.1200/GO.23.00294
work_keys_str_mv AT wilsonbrookee globalcancerdrugdevelopmentareportfromthe2022acceleratinganticanceragentdevelopmentandvalidationmeeting
AT sullivanrichard globalcancerdrugdevelopmentareportfromthe2022acceleratinganticanceragentdevelopmentandvalidationmeeting
AT petorichard globalcancerdrugdevelopmentareportfromthe2022acceleratinganticanceragentdevelopmentandvalidationmeeting
AT abubakarbello globalcancerdrugdevelopmentareportfromthe2022acceleratinganticanceragentdevelopmentandvalidationmeeting
AT boothchristopher globalcancerdrugdevelopmentareportfromthe2022acceleratinganticanceragentdevelopmentandvalidationmeeting
AT werutskygustavo globalcancerdrugdevelopmentareportfromthe2022acceleratinganticanceragentdevelopmentandvalidationmeeting
AT adamscary globalcancerdrugdevelopmentareportfromthe2022acceleratinganticanceragentdevelopmentandvalidationmeeting
AT saintraymondagnes globalcancerdrugdevelopmentareportfromthe2022acceleratinganticanceragentdevelopmentandvalidationmeeting
AT flemingthomasr globalcancerdrugdevelopmentareportfromthe2022acceleratinganticanceragentdevelopmentandvalidationmeeting
AT lyerlykim globalcancerdrugdevelopmentareportfromthe2022acceleratinganticanceragentdevelopmentandvalidationmeeting
AT gralowjulier globalcancerdrugdevelopmentareportfromthe2022acceleratinganticanceragentdevelopmentandvalidationmeeting